{"id":10278,"date":"2025-11-30T11:29:22","date_gmt":"2025-11-30T08:29:22","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10278"},"modified":"2025-11-30T11:29:22","modified_gmt":"2025-11-30T08:29:22","slug":"entresto-nedir-sacubitril-valsartan-mekanizmasi-paradigm-hf-calismasi-ve-kalp-yetersizligi-tedavisi","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10278","title":{"rendered":"Entresto Nedir? Sacubitril Valsartan Mekanizmas\u0131, PARADIGM-HF \u00c7al\u0131\u015fmas\u0131 ve Kalp Yetersizli\u011fi Tedavisi"},"content":{"rendered":"<h2>Entresto Nedir ve Neden Bu Kadar Konu\u015fuluyor?<\/h2>\n<p>\nK\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar aras\u0131nda son y\u0131llar\u0131n en \u00e7ok ses getiren kombinasyonlar\u0131ndan biri, kalp yetersizli\u011fi tedavisinde kullan\u0131lan <strong>Entresto<\/strong>\u2019dur. Etkin maddeleri olan <strong>sacubitril<\/strong> ve <strong>valsartan<\/strong>, klasik ACE inhibit\u00f6rleri ve ARB\u2019lere k\u0131yasla sa\u011fkal\u0131m\u0131 art\u0131ran, hastaneye yat\u0131\u015flar\u0131 azaltan ve ya\u015fam kalitesini iyile\u015ftiren \u00e7arp\u0131c\u0131 sonu\u00e7lar sunmu\u015ftur<br \/>\n(<strong>doi:10.1056\/NEJMoa1409077<\/strong>).\n<\/p>\n<p>\nEntresto, farmakoloji literat\u00fcr\u00fcnde <strong>ARNI (angiotensin receptor\u2013neprilysin inhibitor)<\/strong> s\u0131n\u0131f\u0131n\u0131n ilk temsilcisidir. Yani tek bir hedefe odaklanmak yerine, hem <strong>renin-anjiotensin-aldosteron sistemini (RAAS)<\/strong> bask\u0131lar hem de <strong>natri\u00fcretik peptid sistemini<\/strong> g\u00fc\u00e7lendirir. Bu \u00e7ift y\u00f6nl\u00fc etki profili, onu kalp yetersizli\u011fi tedavisinde \u201coyun de\u011fi\u015ftirici\u201d yapan temel \u00f6zelliktir<br \/>\n(<strong>doi:10.1038\/nrd.2015.5<\/strong>).\n<\/p>\n<h2>Sacubitril ve Valsartan Nas\u0131l \u00c7al\u0131\u015f\u0131r?<\/h2>\n<h3>Sacubitril: Neprilisin \u0130nhibit\u00f6r\u00fc K\u00fc\u00e7\u00fck Molek\u00fcl<\/h3>\n<p>\nSacubitril, bir <strong>prodrug<\/strong> olarak tasarlanm\u0131\u015f, v\u00fccutta aktif metabolitine d\u00f6n\u00fc\u015fen bir <strong>neprilisin inhibit\u00f6r\u00fc<\/strong>d\u00fcr. Neprilisin; natri\u00fcretik peptidler, bradikinin ve di\u011fer vazodilat\u00f6r peptidleri par\u00e7alayan bir enzimdir. Bu enzimi inhibe ederek:\n<\/p>\n<ul>\n<li>Damarlar\u0131n geni\u015flemesini (vazodilatasyon) art\u0131r\u0131r,<\/li>\n<li>Sodyum ve su at\u0131l\u0131m\u0131n\u0131 destekler (natri\u00fcrezis ve di\u00fcrezis),<\/li>\n<li>Kalp \u00fczerindeki hacim ve bas\u0131n\u00e7 y\u00fck\u00fcn\u00fc azalt\u0131r,<\/li>\n<li>Kardiyak remodelling s\u00fcrecini yava\u015flatmaya katk\u0131da bulunur.<\/li>\n<\/ul>\n<p>\nBu mekanizma, kalp yetersizli\u011fi patofizyolojisinde bask\u0131lanm\u0131\u015f durumda olan koruyucu natri\u00fcretik peptid sistemini yeniden \u00f6ne \u00e7\u0131kar\u0131r<br \/>\n(<strong>doi:10.1038\/nrd.2015.5<\/strong>, <strong>doi:10.1016\/j.bmc.2013.11.028<\/strong>).\n<\/p>\n<h3>Valsartan: RAAS Blokaj\u0131n\u0131n G\u00fc\u00e7l\u00fc Aya\u011f\u0131<\/h3>\n<p>\nValsartan ise uzun y\u0131llard\u0131r klinikte kullan\u0131lan bir <strong>anjiyotensin II tip 1 (AT1) resept\u00f6r antagonisti<\/strong>dir. Anjiyotensin II\u2019nin:\n<\/p>\n<ul>\n<li>Damar daralt\u0131c\u0131 (vazokonstrikt\u00f6r),<\/li>\n<li>Sodyum ve su tutucu,<\/li>\n<li>Fibrozis ve hipertrofi art\u0131r\u0131c\u0131<\/li>\n<\/ul>\n<p>\netkilerini bloke eder. B\u00f6ylece kan bas\u0131nc\u0131n\u0131 d\u00fc\u015f\u00fcr\u00fcr, kalbin i\u015f y\u00fck\u00fcn\u00fc azalt\u0131r ve kronik kardiyak stresin yol a\u00e7t\u0131\u011f\u0131 yeniden \u015fekillenmeyi (remodelling) s\u0131n\u0131rlar<br \/>\n(<strong>doi:10.1161\/01.CIR.0000094403.67390.EF<\/strong>).\n<\/p>\n<p>\nBu iki k\u00fc\u00e7\u00fck molek\u00fcl bir araya geldi\u011finde, kalp yetersizli\u011finde hem <strong>\u201cy\u00fck\u00fc azaltan\u201d<\/strong> hem de <strong>\u201cd\u00fczeni yeniden kuran\u201d<\/strong> sinerjik bir farmakolojik kalkan olu\u015fturur<br \/>\n(<strong>doi:10.1038\/nrd.2016.81<\/strong>).\n<\/p>\n<h2>PARADIGM-HF: Neden Bir D\u00f6n\u00fcm Noktas\u0131yd\u0131?<\/h2>\n<p>\nEntresto\u2019nun klinik sahnedeki as\u0131l y\u00fckseli\u015fi, HFrEF (ejeksiyon fraksiyonu azalm\u0131\u015f kalp yetersizli\u011fi) hastalar\u0131nda yap\u0131lan <strong>PARADIGM-HF<\/strong> \u00e7al\u0131\u015fmas\u0131yla oldu<br \/>\n(<strong>doi:10.1056\/NEJMoa1409077<\/strong>). Bu dev randomize klinik \u00e7al\u0131\u015fmada, sacubitril\/valsartan; alt\u0131n standart kabul edilen ACE inhibit\u00f6r\u00fc <strong>enalapril<\/strong> ile kafa kafaya kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131.\n<\/p>\n<p>\nSonu\u00e7lar, kardiyoloji d\u00fcnyas\u0131nda man\u015fet oldu:\n<\/p>\n<ul>\n<li><strong>Kardiyovask\u00fcler \u00f6l\u00fcm veya kalp yetersizli\u011fi nedeniyle hastaneye yat\u0131\u015f<\/strong> riski yakla\u015f\u0131k %20 azald\u0131,<\/li>\n<li><strong>T\u00fcm nedenlere ba\u011fl\u0131 \u00f6l\u00fcm<\/strong> anlaml\u0131 \u015fekilde azald\u0131,<\/li>\n<li>Hastalar\u0131n <strong>semptom skoru ve ya\u015fam kalitesi<\/strong> belirgin iyile\u015fti<br \/>\n  (<strong>doi:10.1001\/jama.2015.15685<\/strong>).<\/li>\n<\/ul>\n<p>\nBu veriler, Avrupa ve Amerikan kalp yetersizli\u011fi k\u0131lavuzlar\u0131n\u0131n h\u0131zla g\u00fcncellenmesine yol a\u00e7t\u0131 ve Entresto, HFrEF tedavisinde birinci basamak temel ajanlardan biri olarak \u00f6nerilmeye ba\u015fland\u0131<br \/>\n(<strong>doi:10.1093\/eurheartj\/ehw128<\/strong>).\n<\/p>\n<h2>K\u00fc\u00e7\u00fck Molek\u00fcl Tasar\u0131m\u0131nda Yeni Paradigma: ARNI Stratejisi<\/h2>\n<p>\nEntresto\u2019nun geli\u015ftirilme s\u00fcreci, modern <strong>k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 tasar\u0131m\u0131&lt;\/strong i\u00e7in ders niteli\u011findedir. Tek bir hedefi \u201cmaksimum\u201d d\u00fczeyde bask\u0131lamak yerine, <strong>iki farkl\u0131 patofizyolojik ekseni orta d\u00fczeyde ama birlikte mod\u00fcle eden<\/strong> bir \u201cpolypharmacology\u201d yakla\u015f\u0131m\u0131 benimsendi<br \/>\n(<strong>doi:10.1038\/nrd.2016.81<\/strong>).\n<\/p>\n<p>\nBu stratejinin sa\u011flad\u0131\u011f\u0131 avantajlar:\n<\/p>\n<ul>\n<li>Daha g\u00fc\u00e7l\u00fc ve s\u00fcrd\u00fcr\u00fclebilir klinik etki,<\/li>\n<li>Birden fazla mekanizmay\u0131 tek tabletle hedefleyerek <strong>ila\u00e7 y\u00fck\u00fcn\u00fc azaltma<\/strong>,<\/li>\n<li>Hasta uyumunda (adherence) belirgin art\u0131\u015f,<\/li>\n<li>Yan etki profilini dengede tutabilme.<\/li>\n<\/ul>\n<p>\nSacubitril\u2019in prodrug olarak tasarlanmas\u0131, oral biyoyararlan\u0131m, metabolik stabilite ve hedef enzimle etkile\u015fim a\u00e7\u0131s\u0131ndan optimize edilmi\u015ftir<br \/>\n(<strong>doi:10.1016\/j.bmc.2013.11.028<\/strong>). Bu da Entresto\u2019yu, ak\u0131ll\u0131 k\u00fc\u00e7\u00fck molek\u00fcl tasar\u0131m\u0131n\u0131n klinik ba\u015far\u0131ya d\u00f6n\u00fc\u015fm\u00fc\u015f nadir \u00f6rneklerinden biri haline getirir.\n<\/p>\n<h2>G\u00fcvenlilik, Yan Etkiler ve Klinik Kullan\u0131mda Dikkat Edilmesi Gerekenler<\/h2>\n<p>\nHer g\u00fc\u00e7l\u00fc k\u00fc\u00e7\u00fck molek\u00fcl gibi, Entresto\u2019nun da dikkatle izlenmesi gereken yan etkileri vard\u0131r:\n<\/p>\n<ul>\n<li><strong>Hipotansiyon<\/strong> (\u00f6zellikle y\u00fcksek doz di\u00fcretik kullanan veya d\u00fc\u015f\u00fck ba\u015flang\u0131\u00e7 tansiyonlu hastalarda),<\/li>\n<li><strong>Hiperkalemi<\/strong>,<\/li>\n<li><strong>B\u00f6brek fonksiyon bozuklu\u011fu<\/strong>,<\/li>\n<li>ACE inhibit\u00f6r\u00fcnden ge\u00e7i\u015fte veya y\u00fcksek riskli gruplarda <strong>anjiyo\u00f6dem<\/strong><br \/>\n  (<strong>doi:10.1161\/CIRCHEARTFAILURE.115.002735<\/strong>).<\/li>\n<\/ul>\n<p>\nKlinik pratikte \u015fu noktalara \u00f6zellikle dikkat edilir:\n<\/p>\n<ul>\n<li>ACE inhibit\u00f6r\u00fcnden Entresto\u2019ya ge\u00e7erken en az <strong>36 saatlik \u201cwashout\u201d<\/strong> s\u00fcresi b\u0131rakmak,<\/li>\n<li>Kan bas\u0131nc\u0131, serum potasyum ve kreatinin d\u00fczeylerini d\u00fczenli takip etmek,<\/li>\n<li>Dozu yava\u015f ve kontroll\u00fc titrasyonla art\u0131rmak,<\/li>\n<li>\u015eiddetli hipotansiyon veya b\u00f6brek fonksiyon bozulmas\u0131nda dozu g\u00f6zden ge\u00e7irmek.<\/li>\n<\/ul>\n<p>\nK\u0131lavuzlar, uygun kan bas\u0131nc\u0131 ve b\u00f6brek fonksiyonu olan, h\u00e2l\u00e2 semptomatik HFrEF hastalar\u0131nda ACE inhibit\u00f6r\u00fc veya ARB yerine sacubitril\/valsartan kullan\u0131m\u0131n\u0131 g\u00fc\u00e7l\u00fc \u015fekilde desteklemektedir<br \/>\n(<strong>doi:10.1093\/eurheartj\/ehw128<\/strong>).\n<\/p>\n<h2>Gelecek Perspektifi: Entresto Yaln\u0131zca Ba\u015flang\u0131\u00e7 m\u0131?<\/h2>\n<p>\nEntresto\u2019nun ba\u015far\u0131s\u0131, <strong>kombine k\u00fc\u00e7\u00fck molek\u00fcl stratejilerinin<\/strong> sadece kalp yetersizli\u011finde de\u011fil, di\u011fer kardiyovask\u00fcler ve metabolik hastal\u0131klarda da kullan\u0131labilece\u011fini g\u00f6sterdi. Sacubitril\/valsartan \u015fu alanlarda da yo\u011fun \u015fekilde ara\u015ft\u0131r\u0131l\u0131yor:\n<\/p>\n<ul>\n<li><strong>HFpEF (korunmu\u015f ejeksiyon fraksiyonlu kalp yetersizli\u011fi)<\/strong> \u2013 PARAGON-HF \u00e7al\u0131\u015fmas\u0131<br \/>\n  (<strong>doi:10.1056\/NEJMoa1908655<\/strong>),<\/li>\n<li><strong>Post-MI remodelling<\/strong> ve erken d\u00f6nemde kalp korumas\u0131,<\/li>\n<li><strong>Diren\u00e7li hipertansiyon<\/strong> ve kompleks kardiyometabolik sendromlar.<\/li>\n<\/ul>\n<p>\nBu tablo, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n tek hedefli \u201cklasik\u201d tasar\u0131mdan \u00e7ok hedefli, a\u011f temelli bir farmakolojiye do\u011fru evrildi\u011finin canl\u0131 bir g\u00f6stergesi. Entresto, bu evrimin klinikte \u015fimdiden hayat kurtaran ilk \u00f6rneklerinden biri olarak \u00f6ne \u00e7\u0131k\u0131yor.\n<\/p>\n<h2>S\u0131k Sorulan Sorular (SSS)<\/h2>\n<h3>1. Entresto (sacubitril\/valsartan) kimler i\u00e7in uygundur?<\/h3>\n<p>\nEntresto, ba\u015fta <strong>ejeksiyon fraksiyonu azalm\u0131\u015f (HFrEF) semptomatik kalp yetersizli\u011fi<\/strong> olan hastalar i\u00e7in uygundur. \u00d6zellikle ACE inhibit\u00f6r\u00fc veya ARB kulland\u0131\u011f\u0131 halde h\u00e2l\u00e2 semptomatik olan, yeterli kan bas\u0131nc\u0131na ve kabul edilebilir b\u00f6brek fonksiyonuna sahip hastalarda k\u0131lavuzlar taraf\u0131ndan \u00f6nerilmektedir<br \/>\n(<strong>doi:10.1093\/eurheartj\/ehw128<\/strong>).\n<\/p>\n<h3>2. Entresto, ACE inhibit\u00f6rlerinden ger\u00e7ekten daha m\u0131 etkili?<\/h3>\n<p>\nPARADIGM-HF \u00e7al\u0131\u015fmas\u0131nda sacubitril\/valsartan; enalaprile g\u00f6re kardiyovask\u00fcler \u00f6l\u00fcm veya kalp yetersizli\u011fi nedeniyle hastaneye yat\u0131\u015f riskini yakla\u015f\u0131k %20 oran\u0131nda azaltm\u0131\u015ft\u0131r<br \/>\n(<strong>doi:10.1056\/NEJMoa1409077<\/strong>). Bu nedenle, uygun hastalarda ACE inhibit\u00f6rlerine k\u0131yasla <strong>daha \u00fcst\u00fcn bir se\u00e7enek<\/strong> olarak kabul edilmektedir.\n<\/p>\n<h3>3. Entresto ile ACE inhibit\u00f6r\u00fc birlikte kullan\u0131labilir mi?<\/h3>\n<p>\nHay\u0131r. Entresto, ARB i\u00e7erdi\u011fi ve neprilisin inhibisyonu bradikinin d\u00fczeylerini art\u0131rabildi\u011fi i\u00e7in, ACE inhibit\u00f6rleriyle birlikte kullan\u0131m\u0131 <strong>anjiyo\u00f6dem riskini belirgin art\u0131r\u0131r<\/strong>. ACE inhibit\u00f6r\u00fcnden Entresto\u2019ya ge\u00e7i\u015f yap\u0131lacaksa, ila\u00e7 kesildikten sonra en az <strong>36 saat beklenmelidir<\/strong><br \/>\n(<strong>doi:10.1161\/CIRCHEARTFAILURE.115.002735<\/strong>).\n<\/p>\n<h3>4. Entresto b\u00f6brek fonksiyonunu nas\u0131l etkiler?<\/h3>\n<p>\nBaz\u0131 hastalarda kreatinin d\u00fczeyinde y\u00fckselme ve GFR\u2019de d\u00fc\u015f\u00fc\u015f g\u00f6r\u00fclebilir. Ancak \u00e7al\u0131\u015fmalar, ACE inhibit\u00f6rlerine k\u0131yasla b\u00f6brek fonksiyonu \u00fczerindeki etkinin genellikle benzer veya daha iyi tolere edilebilir oldu\u011funu g\u00f6stermektedir<br \/>\n(<strong>doi:10.1093\/eurheartj\/ehw128<\/strong>). Yine de ya\u015fl\u0131, diyabetik veya \u00f6nceden kronik b\u00f6brek hastal\u0131\u011f\u0131 olan hastalarda d\u00fczenli b\u00f6brek fonksiyon takibi \u015fartt\u0131r.\n<\/p>\n<h3>5. Entresto kullan\u0131rken kan bas\u0131nc\u0131m \u00e7ok d\u00fc\u015ferse ne yapmal\u0131y\u0131m?<\/h3>\n<p>\nHipotansiyon, Entresto\u2019nun en s\u0131k g\u00f6r\u00fclen yan etkilerinden biridir. Bu durumda:\n<\/p>\n<ul>\n<li>Di\u00fcretik dozu azalt\u0131labilir,<\/li>\n<li>Entresto dozu d\u00fc\u015f\u00fcr\u00fclebilir veya ge\u00e7ici olarak kesilebilir,<\/li>\n<li>Di\u011fer antihipertansif ila\u00e7lar g\u00f6zden ge\u00e7irilebilir.<\/li>\n<\/ul>\n<p>\n\u015eiddetli ba\u015f d\u00f6nmesi, bay\u0131lma hissi veya g\u00f6\u011f\u00fcs a\u011fr\u0131s\u0131 gibi belirtiler varsa, <strong>vakit kaybetmeden hekime ba\u015fvurmak<\/strong> gerekir<br \/>\n(<strong>doi:10.1001\/jama.2015.15685<\/strong>).\n<\/p>\n<h2>Kaynaklar (DOI)<\/h2>\n<p>\n10.1056\/NEJMoa1409077; 10.1001\/jama.2015.15685; 10.1038\/nrd.2015.5; 10.1161\/01.CIR.0000094403.67390.EF; 10.1038\/nrd.2016.81; 10.1016\/j.bmc.2013.11.028; 10.1161\/CIRCHEARTFAILURE.115.002735; 10.1056\/NEJMoa1908655; 10.1093\/eurheartj\/ehw128<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Entresto (sacubitril\/valsartan) nedir, nas\u0131l \u00e7al\u0131\u015f\u0131r ve neden kalp yetersizli\u011fi tedavisinde \u201coyun de\u011fi\u015ftirici\u201d kabul edilir? ARNI s\u0131n\u0131f\u0131, RAAS blokaj\u0131, natri\u00fcretik peptid sistemi ve PARADIGM-HF \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131n\u0131 detayl\u0131 inceleyin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[835,837,836],"class_list":["post-10278","post","type-post","status-publish","format-standard","hentry","category-molekul","tag-entresto","tag-kalp-yetersizligi-tedavisi","tag-sacubitril-valsartan"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10278"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10278\/revisions"}],"predecessor-version":[{"id":10279,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10278\/revisions\/10279"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}